Implantica AG (STU:8IM1)

Q3 2025 Implantica AG Earnings Call Transcript

Oct 31, 2025 / 02:00 PM GMT

Release Date Price: €4.65 (-2.42%)

Transcript

Key Points

Positve

Implantica AG (FRA:8IM1) has developed two platform technologies, an e-health platform and a wireless energizing platform, which have the potential to revolutionize healthcare.
The company has a strong patent portfolio, with the eHealth platform covered by 25,000 pages of patents, providing a robust competitive moat.
Implantica AG (FRA:8IM1) has passed multiple FDA pre-approval inspections, indicating progress towards potential FDA approval.
The company's main competitor is withdrawing from all markets except the US, which could provide a competitive advantage for Implantica AG (FRA:8IM1).
The company has a solid financial position with no interest-bearing debt and a cash reserve of €53.3 million.

Negative

Net sales for the third quarter were only €365,000, representing a modest increase of 6% compared to the same period last year.
The company's operating loss for the third quarter amounted to €4.4 million, highlighting ongoing financial challenges.
The FDA approval process is complex and time-consuming, with changing requirements that can delay timelines.
There are minor observations from FDA inspections that need to be addressed, although they are not expected to impact the approval process.
The company has paused some development activities, such as the random control trial versus Nissan, to focus on FDA approval, which may delay other projects.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IMPsdba.ST - Implantica AG
Q3 2025 Implantica AG Earnings Call
Oct 31, 2025 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the Implannia Q3 2025 report presentation. For the first part of the presentation, the participants will be in listen-only mode. During the questions and answer session, participants are able to ask questions by dialing und key 5 on their telephone keypad. Now I will hand the con.

Speak CEO Peter Forreis Ornberg and Chief Corporate Officer Nicole Pearson, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you.

So welcome to Implantica's Q3 investor presentation.

And I guess you know me by now, but I have invested lots of money and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.